CN1064232C - 一种治疗心脏病药物的非冻干型粉针制剂及制备方法 - Google Patents
一种治疗心脏病药物的非冻干型粉针制剂及制备方法 Download PDFInfo
- Publication number
- CN1064232C CN1064232C CN96116525A CN96116525A CN1064232C CN 1064232 C CN1064232 C CN 1064232C CN 96116525 A CN96116525 A CN 96116525A CN 96116525 A CN96116525 A CN 96116525A CN 1064232 C CN1064232 C CN 1064232C
- Authority
- CN
- China
- Prior art keywords
- acid
- amrinone
- injection
- solvent
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002347 injection Methods 0.000 title claims abstract description 32
- 239000007924 injection Substances 0.000 title claims abstract description 32
- 239000000843 powder Substances 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title claims description 12
- 238000004108 freeze drying Methods 0.000 title description 2
- 208000019622 heart disease Diseases 0.000 title 1
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 claims abstract description 53
- 229960002105 amrinone Drugs 0.000 claims abstract description 53
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 229940079593 drug Drugs 0.000 claims abstract description 17
- 239000002904 solvent Substances 0.000 claims abstract description 17
- 239000003708 ampul Substances 0.000 claims abstract description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 16
- 238000002425 crystallisation Methods 0.000 claims description 14
- 230000008025 crystallization Effects 0.000 claims description 14
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 10
- 239000003963 antioxidant agent Substances 0.000 claims description 9
- 230000003078 antioxidant effect Effects 0.000 claims description 9
- 235000006708 antioxidants Nutrition 0.000 claims description 9
- 239000004310 lactic acid Substances 0.000 claims description 8
- 235000014655 lactic acid Nutrition 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 6
- 235000010265 sodium sulphite Nutrition 0.000 claims description 6
- 239000008215 water for injection Substances 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 3
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004327 boric acid Substances 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- DUYAAUVXQSMXQP-UHFFFAOYSA-N ethanethioic S-acid Chemical compound CC(S)=O DUYAAUVXQSMXQP-UHFFFAOYSA-N 0.000 claims description 2
- 235000019256 formaldehyde Nutrition 0.000 claims description 2
- 239000000174 gluconic acid Substances 0.000 claims description 2
- 235000012208 gluconic acid Nutrition 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 229940099563 lactobionic acid Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 235000006109 methionine Nutrition 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 2
- 239000001117 sulphuric acid Substances 0.000 claims description 2
- 235000011149 sulphuric acid Nutrition 0.000 claims description 2
- 229940035024 thioglycerol Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 239000003643 water by type Substances 0.000 claims description 2
- 239000013078 crystal Substances 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 abstract description 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 230000008014 freezing Effects 0.000 abstract 1
- 238000007710 freezing Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 10
- 206010019280 Heart failures Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 7
- 238000011068 loading method Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000024883 vasodilation Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 201000006306 Cor pulmonale Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003130 cardiopathic effect Effects 0.000 description 1
- 230000001426 cardiotropic effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种治疗心血管病药物的非冻干型粉针制剂。该制剂是由一支内含作为活性成份的氨力农(Amrinone)药物(结晶或结晶性粉末)与一支内含注射用溶剂(液体)的安瓿瓶组合而成的。在使用时将注射用溶剂注入氨力农药物溶解即可。该制剂稳定性好,使用方便。本发明提供了制备方法。
Description
本发明涉及药物制剂及制备方法。
氨力农(Amrinone),又名氨吡酮,化学名为5-氨基-3,4′双吡啶-6(1H)酮,可用于制备治疗心脏病的药物。现用的多为冻干型制剂和注射液,但是冻干型制剂在制备时受设备和生产条件限制且贮存时会发生沉淀浑浊及变色现象,注射液贮存时会发生沉淀浑浊现象,影响了临床应用。
本发明的目的是在于克服上述缺点,研制一种新的剂型,使其稳定性好,质量可靠。
本发明人经过考察,发现当氨力农原料药单独存放,在既无抗氧剂保护,也无充氮保护,室温自然条件下,放置四年以上,外观和内在质量均无任何改变,因而极大地延长了使用期。
本发明提供了一种氨力农粉针制剂。该制剂为一种非冻干型的组合式注射剂,具体是由一支内含作为活性成份的氨力农药物结晶小瓶与一支内含注射用辅料的安瓿瓶组合而成的。其中氨力农药物小瓶中含有氨力农10-500毫克,注射用溶剂是由酸、抗氧剂和注射用水组成的,其中酸含量为14-180毫克/支、抗氧剂为0-5%。
本发明的另一个目的是提供了上述氨力农粉针剂的制备方法,该方法包括下列步骤:
(1)制备氨力农药物结晶:
将氨力农加10-1000倍量的注射用水,煮沸溶解,在无菌条件下,过滤,滤液静置自然冷却,收集结晶,40-115℃干燥2-6小时,定量、无菌分装于瓶中(10-500毫克/每瓶),再置40-115℃干燥1-4小时后,加胶塞、压铝盖、包装;
(2)制备注射用溶剂:
将抗氧剂加5000倍注射用水,溶解后,加入酸至PH为2-3,加入活性炭、过滤、无菌分装入安瓿,灭菌、试漏、印字和包装,1-50ml/每支;
(3)将上述制得的氨力农药物结晶1-10瓶与注射用溶剂1-10支放在一个包装盒中。有时为防止溶剂安瓿破损,在盒中多装一支注射用溶剂。
上述注射用溶剂中所述的酸可以为乳酸、马来酸、枸椽酸、葡萄糖酸、重酒石酸、乳糖酸、琥珀酸、盐酸、硝酸、硫酸、醋酸、磷酸、硼酸或其它可药用的无机酸和有机酸;
所述的抗氧剂可以为焦亚硫酸钠、亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、甲醛合亚硫酸氢钠、硫脲、维生素C、半胱氨酸、蛋氨酸、硫代乙酸、硫代甘油等。
本发明的氨力农粉针剂在使用前将一支注射用溶剂注入一瓶氨力农药物结晶内,振摇溶解即可。
本发明的氨力农粉针剂临床用于治疗充血性心力衰竭患者有明显的疗效,结果如下:
一、临床疗效与适应症
1、本研究对867例充血性心力衰竭患者采用静脉推注负荷量后继静脉滴注或直接静脉滴注5-14天后的疗效进行考察表明,氨力农粉针剂可明显改善心力衰竭患者心功能,显效、有效率分别为39.1%、53.9%,总有效率达93%,适应于不同年龄组各种病因所致的急慢性充血性心力衰竭。尤其对风心病、心肌病所致的晚期顽固性心力衰竭有一定疗效,对于肺心病、急性心肌梗塞所致心衰仍然安全有效,本试验总有效率高于Ⅰ、Ⅱ期临床试验结果,可能与部分病人同时合并应用血管扩张剂有关。
2、在全程用负荷剂量组中,心功能改善1级、2级或无改,采用的一次负荷量与每分钟每公斤体重的静滴量三组间无明显差异(P>0.1),临床一般情况,治疗前心功能级别、疗程与合并用药,各组间也无显著性(P>0.1)。与Ⅱ期临床试验结果相似。提示疗效的差别不是由于应用药物剂量大小不同所致,可能与心肌本身病变的严重程度有关。
3、全程用负荷剂量与单纯静脉滴注两种不同用药方式比较,治疗前心功能级别和治疗后心功能改善1级、2级或无改善者两组间无差异,而每分钟每公斤体重静滴量,静脉滴注组明显大于全程负荷组,分别为8.8=1.1ug/分/公斤,6.9=1.7ug/分/公斤(P<0.001),两组合并应用强心、利尿剂无差别(P<0.1),而静脉滴注组合并用两种血管扩张剂多于全程负荷组(P<0.01),提示采用直接静脉滴注方式,且加大其每公斤体重每分钟滴注量,有可能与采用全程负荷量用药方式有相同疗效,但由于其中有血管扩张剂的因素参与,故不能完全肯定其疗效。有待控制各种因素后进一步证实。
二、结论:
1、氨力农粉针剂适应于各种病因所致的急性与慢性充血性心力衰竭病人,总有效率达92.96%,对急性心肌梗塞、肺心病所致心衰也有显著效果,尤其对晚期难治性心衰有一定疗效。
2、极少数患者在推注负荷量时有可能导致低血压和心律失常发生,但并不严重,容易处理,不影响治疗;对肝肾功能影响很小;轻度消化道反应,血小板降低相对多见,但并不影响治疗。疗程由5-7天延长到8-14天仍然比较安全。
3、采用直接静脉滴注方式,且增加其每分钟每公斤静滴量有可能与使用负荷量的疗效相同,而减少了低血压与心律失常的发生,使其更安全。
本研究表明,氨力农为有效,安全的抗充血性心力衰竭制剂,值得推广应用。
本发明的氨力农粉针剂中氨力农纯化结晶品的质量检验如下:
本品为氨力农的无菌粉末或结晶,含氨力农应为标示量的90.0-110%。性状为淡黄棕色针状结晶或结晶性粉末。其它检测项目应符合中国药典1990年版的有关规定。
本发明的氨力农粉针制剂的注射用溶剂的质量检验如下:本品为灭菌水溶液。含乳酸应为标示量的90.0-110%。性状为无色澄清液体。其它检测项目应符合中国药典1990年版的有关规定。
本发明使用的氨力农药物结晶室温留样考察结果如下:
批号 | 考察时间月 | 考察项目 | |||
外观性状 | 色谱降解产物 | 干燥失重% | 含量% | ||
0 | 淡黄棕色结晶性粉末 | 未见杂质斑点 | 99.6 | ||
1 | 淡黄棕色结晶性粉末 | 未见杂质斑点 | 99.61 | ||
3 | 淡黄棕色结晶性粉末 | 未见杂质斑点 | 99.60 |
上述结果表明氨力农药物结晶或结晶性粉末在五年的室温留样考察期中,各项主要指标均无明显变化,说明在五年内是稳定的。
本发明使用的氨力农(氨吡酮)的小鼠急性毒性试验结果如下:
一、试验材料和方法
1、实验药品:
实验所需氨吡酮由中国药科大学合成提供,淡黄色结晶,分子量187.2,化学结构式C10H9N2O。
2、动物:
昆明种小鼠(本校动物室提供),随机分3-4组,每组10只,小鼠体重为20±2g。
3、给药途径:
口服给药按AloHsi法用0.5N乳酸配成5%氨吡酮溶液,然后用生理盐水稀释所需浓度,用灌胃针经,给药,对照组用0.25乳酸溶液给予,各组动物在给药前4小时开始禁食。
静脉注射氨吡酮溶液配制方法同上,小鼠尾静脉注射速度为1ml/min。
4、试验方法:实验小鼠分成3-4个剂量组,每组实验设乳酸对照组。口服药各组间距比值为1∶0.6,静脉给药组间距比值为1∶0.8。给药后观察小鼠的一般症状记录7天内各组死亡率,用寇氏法(Karber)计算LD40值及其95%可信限,观察期间死亡动物即刻尸检和组织学检查。
二、试验结果:
小鼠静脉注射氨吡酮的LD50为114mg/kg,95%可信限为104-125mg/kg,小鼠口服给氨吡酮的LD50为257mg/kg95%可信限为210-314mg/kg。给药后小鼠出现活动减少,食欲减退,后肢麻痹,四肢匐伏呼吸逐渐减慢而停止。心脏最终停止搏动。死亡小鼠腹腔肠道充血明显。局部可见点状及片状出血。死亡时间多在24小时内发生。最快死亡时间可在大剂量注射后3小时。组织学检查:给药组除肺淤血、间质增厚、炎性细胞浸润外,其他脏器如心、肾、脾、脑均无异常现象。
对照组(乳酸)小鼠无异常发现。均存活健在。
三、小结:
据Alousi等所进行的氨吡酮(氨力农)毒性研究中。小鼠口服氨吡酮LD50为288mg/kg(可信限239-346mg/kg),静脉注射氨吡酮LD50为150mg/kg(可信限111-178mg/kg)。我室试验结果:口服给药LD50为257mg/kg。静脉给药LD50为114mg/kg与Alousi报道较为接近。
上述结果表明本发明的非冻干型氨力农粉针剂是安全有效的,并且由于稳定性好,贮存方便,延长了使用期限。本发明的制备工艺简便,适宜于规模型工业化生产。
实例1、制备氨力农灭菌结晶粉末制剂
取1克氨力农加注射用水1000毫升煮沸溶解,在无菌条件下,除菌过滤,滤液静置自然冷却至淡黄棕色结晶性粉末,收集结晶,置105℃干燥2小时,无菌分装于小瓶中,每瓶50毫克,再置80℃干燥半小时,加胶塞、压铝盖。
实例2、制备注射用溶剂
取1.25克焦亚硫酸钠,用注射用水溶解后,加乳酸80毫升至PH为2.2-2.3,加活性炭、过滤,无菌分装、封口、灭菌、试漏、印字。
实例3、制备氨力农粉针剂组盒
取五支按实例1制得的氨力农药物小瓶与六支按实例2制得的注射用溶剂安瓿瓶同装于一个盒中即成。
Claims (3)
1、一种氨力农粉针剂,其特征在于该粉针剂是由一支内含作为活性成份的氨力农药物小瓶与一支内含注射用溶剂的安瓿瓶组合而成的,其中氨力农药物小瓶中含有氨力农10-500毫克,注射用溶剂是由酸、抗氧剂和注射用水组成的,其中酸含量为14-180毫克/支,抗氧剂为0-5%。
2、一种如权利要求1所述的氨力农粉针剂的制备方法,其特征在于该方法包括下列步骤:
(1)制备氨力农药物结晶:
将氨力农加10-1000倍量的注射用水,煮沸溶解,在无菌条件下,过滤,滤液静置自然冷却,收集结晶,40-115℃干燥2-6小时,定量、无菌分装于瓶中,每瓶含10-500毫克无菌氨力农结晶或结晶性粉末,再置40-115℃干燥1-4小时后,加胶塞、压铝盖、包装;
(2)制备注射用溶剂:
将抗氧剂加5000倍注射用水,溶解后,加入酸至PH为2-3,加入活性炭、过滤、无菌分装入安瓿,灭菌、试漏、印字和包装,1-50ml/每支;
(3)将上述制得的氨力农药物结晶1-10瓶与注射用溶剂1-10支放在一个包装盒中。
3、根据权利要求1或2所述的氨力农粉针剂,其特征在于其中所述注射用溶剂中的酸可以为乳酸、马来酸、枸椽酸、葡萄糖酸、重酒石酸、乳糖酸、琥珀酸、盐酸、硝酸、硫酸、醋酸、磷酸、硼酸或其它可药用的无机酸和有机酸;抗氧剂可以为焦亚硫酸钠、亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、甲醛合亚硫酸氢钠、硫脲、维生素C、半胱氨酸、蛋氨酸、硫代乙酸或硫代甘油。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN96116525A CN1064232C (zh) | 1996-10-04 | 1996-10-04 | 一种治疗心脏病药物的非冻干型粉针制剂及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN96116525A CN1064232C (zh) | 1996-10-04 | 1996-10-04 | 一种治疗心脏病药物的非冻干型粉针制剂及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1178670A CN1178670A (zh) | 1998-04-15 |
CN1064232C true CN1064232C (zh) | 2001-04-11 |
Family
ID=5123624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN96116525A Expired - Lifetime CN1064232C (zh) | 1996-10-04 | 1996-10-04 | 一种治疗心脏病药物的非冻干型粉针制剂及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1064232C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101926800A (zh) * | 2010-07-23 | 2010-12-29 | 陈益智 | 含有氨力农的药用组合物及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5262650A (en) * | 1975-11-19 | 1977-05-24 | Nichicon Capacitor Ltd | Metod of manufacturing plactic film capacitor |
-
1996
- 1996-10-04 CN CN96116525A patent/CN1064232C/zh not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5262650A (en) * | 1975-11-19 | 1977-05-24 | Nichicon Capacitor Ltd | Metod of manufacturing plactic film capacitor |
Non-Patent Citations (1)
Title |
---|
《上海医学》17(8) 1994.1.1 胡铭芬等,氨力农治疗充血性心力衰竭12例临床观察 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101926800A (zh) * | 2010-07-23 | 2010-12-29 | 陈益智 | 含有氨力农的药用组合物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1178670A (zh) | 1998-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0409450B1 (pt) | composições farmacêuticas, úteis para o tratamento ou controle de infecções bacterianas por administração parenteral, processos para a sua produção e respectivos usos | |
CN101327193A (zh) | 一种氯诺昔康冻干粉针剂及其制备方法 | |
FI78837B (fi) | Foerfarande foer framstaellning av en foer injektionsadministration laemplig, stabil och saltsyrahaltig vattenloesning av cis-platina. | |
CN1126547C (zh) | 香菇多糖冻干粉针剂及其制备方法 | |
CN1823768A (zh) | 西咪替丁冻干组合物 | |
CN1064232C (zh) | 一种治疗心脏病药物的非冻干型粉针制剂及制备方法 | |
CN101912361B (zh) | 一种盐酸头孢替安/无水碳酸钠药物组合物混悬注射剂及其新应用 | |
CN1813700A (zh) | 丙磺舒钠与青霉素类抗生素组成复方针剂 | |
CN101028250A (zh) | 藤黄酸脂质体及其冻干粉针剂与制备方法 | |
CN101181243A (zh) | 一种环磷腺苷冻干制剂及其制备方法 | |
DE60022759T2 (de) | Erythropoietin formulierungen des mehrfachdosis-typs | |
CN100502878C (zh) | 夫西地酸钠组合物及其冻干制剂制备方法 | |
CN1404827A (zh) | 硫普罗宁制剂 | |
CN1836651A (zh) | 左旋舒必利注射剂的制备方法 | |
CN1263454C (zh) | 磷苯妥英钠粉针剂及其制备方法 | |
CN1186094C (zh) | 具有促思维记忆功能的吡拉西坦药物组合物及其制备方法 | |
CN1235575C (zh) | 注射用辅酶q10无菌冻干制剂及其制备方法 | |
CN1562000A (zh) | 4-羟基-2-氧代-1-吡咯烷乙酰胺冻干制剂及其制备方法 | |
CN1850097A (zh) | 灯盏花乙素注射制剂及其制备方法 | |
CN101530391B (zh) | 一种磷酸肌酸钠脂质体冻干制剂 | |
CN101129374B (zh) | 长春氟宁药物组合物及其制备方法与应用 | |
CN111671912A (zh) | 含腺苷钴胺的组合物、冻干粉及其制备方法、注射用药物 | |
CN1562147A (zh) | 黄芩提取物冻干粉针剂及其制备方法 | |
CN1526399A (zh) | 注射用甘草酸二铵冻干粉针剂及其制备方法 | |
CN100336557C (zh) | 一种生长抑素的水溶液制剂、其制备方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CX01 | Expiry of patent term |
Granted publication date: 20010411 |
|
EXPY | Termination of patent right or utility model |